PM-Scl antibody in serum

Clinical significance

• present in ~ 1/4 of patients with the polymyositis/scleroderma overlap syndrome, 8% of patients with polymyositis alone & 2-5% of patients with scleroderma alone

More general terms

• PM-Scl antibody

More specific terms

• PM-SCL-100 Ab in serum
• PM-SCL-75 Ab in serum

Additional terms

• exosome complex exonuclease RRP45 (polymyositis/scleroderma autoantigen 1, autoantigen PM/Scl 1, polymyositis/scleroderma autoantigen 75 kD, PM/Scl-75, P75 polymyositis-scleroderma overlap syndrome associated autoantigen, EXOSC9, PMSCL1)